What is a stock summary page? Click here for an overview.
Business Description
Compare
Compare
Traded in other countries / regions
506128.India IPO Date
2009-09-15Description
Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.02 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.95 | |||||
| Debt-to-EBITDA | 2.75 | |||||
| Interest Coverage | 3.43 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.03 | |||||
| Beneish M-Score | -2.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.8 | |||||
| 3-Year EBITDA Growth Rate | 21.4 | |||||
| 3-Year FCF Growth Rate | -275.5 | |||||
| 3-Year Book Growth Rate | 17.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.7 | |||||
| 9-Day RSI | 56.69 | |||||
| 14-Day RSI | 52.54 | |||||
| 3-1 Month Momentum % | -44.44 | |||||
| 6-1 Month Momentum % | -39.01 | |||||
| 12-1 Month Momentum % | -36.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.91 | |||||
| Quick Ratio | 0.59 | |||||
| Cash Ratio | 0.02 | |||||
| Days Inventory | 76.22 | |||||
| Days Sales Outstanding | 60.49 | |||||
| Days Payable | 47.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.5 | |||||
| Shareholder Yield % | -18.33 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 33.02 | |||||
| Operating Margin % | 10.07 | |||||
| Net Margin % | 5.86 | |||||
| FCF Margin % | -8.94 | |||||
| ROE % | 14.93 | |||||
| ROA % | 6.17 | |||||
| ROIC % | 8.67 | |||||
| 3-Year ROIIC % | -14.94 | |||||
| ROC (Joel Greenblatt) % | 14.14 | |||||
| ROCE % | 19.26 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 11.02 | |||||
| PE Ratio without NRI | 11.08 | |||||
| Shiller PE Ratio | 19.02 | |||||
| PEG Ratio | 0.62 | |||||
| PS Ratio | 0.64 | |||||
| PB Ratio | 1.52 | |||||
| Price-to-Tangible-Book | 1.7 | |||||
| Price-to-Operating-Cash-Flow | 7.52 | |||||
| EV-to-EBIT | 9.68 | |||||
| EV-to-EBITDA | 7.06 | |||||
| EV-to-Revenue | 1.04 | |||||
| EV-to-FCF | -11.4 | |||||
| Price-to-GF-Value | 1.09 | |||||
| Price-to-Projected-FCF | 3.76 | |||||
| Price-to-DCF (Earnings Based) | 1.11 | |||||
| Price-to-Median-PS-Value | 1.73 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.46 | |||||
| Price-to-Graham-Number | 0.88 | |||||
| Earnings Yield (Greenblatt) % | 10.34 | |||||
| FCF Yield % | -13.84 | |||||
| Forward Rate of Return (Yacktman) % | 20 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Parnax Lab Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 1,850.685 | ||
| EPS (TTM) (₹) | 9.436 | ||
| Beta | 1.74 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.11 | ||
| Volatility % | 78.68 | ||
| 14-Day RSI | 52.54 | ||
| 14-Day ATR (₹) | 3.91216 | ||
| 20-Day SMA (₹) | 101.3825 | ||
| 12-1 Month Momentum % | -36.21 | ||
| 52-Week Range (₹) | 81 - 193.5 | ||
| Shares Outstanding (Mil) | 11.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Parnax Lab Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Parnax Lab Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Parnax Lab Ltd Frequently Asked Questions
What is Parnax Lab Ltd(BOM:506128)'s stock price today?
The current price of BOM:506128 is ₹104.00. The 52 week high of BOM:506128 is ₹193.50 and 52 week low is ₹81.00.
When is next earnings date of Parnax Lab Ltd(BOM:506128)?
The next earnings date of Parnax Lab Ltd(BOM:506128) is .
Does Parnax Lab Ltd(BOM:506128) pay dividends? If so, how much?
Parnax Lab Ltd(BOM:506128) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers